REFERENCES: 1. Gopalakrishnan UA, Joshi AS, Giri R, Shah SJ, Shukla J, Maheshwari S, et al. Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III Active-Controlled Study. Diabetes Obes Metab. 2026;0:1-10. 2. Data on File. Sun Pharma, South Africa. Semagard Bioequivalence Study [SEM01024]. 3. Semagard Professional Information. Ranbaxy Pharmaceuticals (Pty) Ltd, South Africa. July 2026. 4. Cleveland Clinic. GLP-1 Agonists: What They Are, How They Work & Side Effects. [Internet] 2023 Jul 3 [Cited 2026 Apr 24]. Available from: https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists. 5. Cleveland Clinic. Diabetes. [Internet] 2023 Feb 17 [Cited 2026 May 14]. Available from: https://my.clevelandclinic.org/health/diseases/7104-diabetes. 6. Semagard Patient Information Leaflet. Ranbaxy Pharmaceuticals (Pty) Ltd, South Africa. July 2026. 7. Bekele H, Asefa A, Getachew B, Belete AM. Barriers and Strategies to Lifestyle and Dietary Pattern Interventions for Prevention and Management of TYPE-2 Diabetes in Africa, Systematic Review. J Diabetes Res. 2020;2020:7948712. 8. Chacko E, Signore C. Five Evidence-Based Lifestyle Habits People With Diabetes Can Use. Clin Diabetes J. 2020;38(3):273-284. 9. Peter PI, Steinberg WJ, Van Rooyen C, Botes J. Type 2 diabetes mellitus patients’ knowledge, attitude and practice of lifestyle modifications. Health SA Gesondheid. 2022;27(0):a1921. 10. Tang Y, Chen Y, Zhou Y, Wu B, Zhang S, Gong Y, et al. Global burden of Type 2 Diabetes Mellitus attributable to dietary risks in elderly adults: insights from the Global Burden of Disease study 2021. Front Nutr. 2025;12:1557923. 11. ADA Nutrition & Wellness Team. What is the Diabetes Plate? [Internet] 2025 Jan 15 [Cited 2026 May 5]. Available from: https://diabetesfoodhub.org/blog/what-diabetes-plate. 12. Cleveland Clinic. Oral Diabetes Medications: Types & How They Work. [Internet] 2022 Nov 23 [Cited 2026 May 4]. Available from: https://my.clevelandclinic.org/health/articles/12070-oral-diabetes-medications. 13. Mayo Clinic Staff. Diabetes treatment: Medications for type 2 diabetes. [Internet] 2025 May 23 [Cited 2026 May 4]. Available from: https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/in-depth/diabetes-treatment/art-20051004. 14. American Diabetes Association. What Are My Options for Type 2 Diabetes Medications? [Internet] [Cited 2026 May 4]. Available from: https://diabetes.org/health-wellness/medication/oral-other-injectable-diabetes-medications. 15. Coetzee A. An introduction to insulin use in type 2 diabetes mellitus. S Afr Fam Pract. 2023;65(1):a5702.
S4 SEMAGARD (Solution for Injection). Reg. No.: 61/21.13/0768. Each 1 ml solution contains 1,34 mg of semaglutide. Preservative: phenol 5,50 mg/ml (0.55 % m/v). Contains propylene glycol 14 mg/ml.
SEMAGARD 0,25 mg and 0,5 mg/dose pen: Each pre-filled pen contains 2 mg semaglutide in 1,5 ml solution.
SEMAGARD 1 mg/dose pen: Each pre-filled pen contains 4 mg semaglutide in 3 ml solution. For full prescribing information, refer to the Professional Information approved by the Regulatory Authority.
Applicant: Ranbaxy Pharmaceuticals (Pty) Ltd., a Sun Pharma company. Reg. No. 1993/003111/07. 14 Lautre Road, Stormill Ext.1, Roodepoort, 1724. Tel: +27 11 495 0100. www.sunpharma.com.
Promotion No.: SEM/05-2026/04/Website/KG.
Disclaimer: This page provides general guidance on the use, storage, and safety of the product for the patients who have been prescribed this medicine by a registered medical practitioner. This shall neither be construed as a Promotional Activity nor constitute as medical advice. Since, this is solely for educational purposes, the contents hereof shall not be relied upon as a substitute for professional consultation. Anyone accessing this website shall be bound by these terms and the Company shall bear no responsibility or liability for any use of the product without a valid prescription or for any misuse arising from non adherence to prescribed instructions. Users must follow the directions provided in the Patient Information Leaflet and the advice of their treating Registered Medical Practitioner.
